NCT06438796Not yet recruitingPhase 2
Blinatumomab Maintenance After Allo-HSCT
Efficacy and Safety of Blinatumomab Maintenanceafter Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Acute B-lymphoblastic Leukemia: a Multicenter, Open-label, Randomized Controlled Study
Source: ClinicalTrials.gov · Last updated 3 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To evaluate the safety and efficacy of Blinatumomab maintenance after allogeneic hematopoietic stem cell transplantation for high-risk acute B-lymphoblastic leukemia.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- First submitted
- 23 May 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Ruijin Hospital
- NCT number
- NCT06438796
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 59
- From 1 Jul 2024 to the primary completion date, 1 Jul 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active hepatitis B
- HIV-infected
- Active infections; acute and chronic GVHD requiring systemic immunosuppressive therapy;
- severe impairment of vital organ function
Other
- CR/MRD negative before blinatumomab maintenance
- Those judged by the investigator to be unsuitable for participation in this trial.
Who the study is looking for
- Age 16-65 years
- Diagnosis with acute B-lymphoblastic leukemia (B-ALL) expressed CD19
- High-risk group B-ALL
- Have suitable hematopoietic stem cell donors
- No dysfunction of vital organs
Age in the registry: 16 years to 65 years · Sex: All · Does not accept healthy volunteers
Related publications
- Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.J Natl Compr Canc Netw · 2025 · PMID 41671463
This page is information, not medical advice. Discuss any trial with your doctor.